ISTH 2021 Congress Archives - ISTH Congress Abstracts

Abstract Number: LB 01.1

Prevention Of Arterial And Venous Vascular Events In Symptomatic Peripheral Arterial Disease Patients After Lower Extremity Revascularization in the VOYAGER PAD trial: Dual Anticoagulant/Antiplatelet Regimen Vs Antiplatelet Therapy Alone

S.D. Berkowitz¹, R.M. Bauersachs², M. Szarek¹, M.R. Nehler¹, E.S. Debus³, M.R. Patel⁴, S.S. Anand⁵, C.N. Hess¹, E. Muehlhofer⁶, L.P. Haskell⁷, M.P. Bonaca¹
Abstract Number: LB 01.2

Abelacimab for Prevention of Venous Thromboembolism

P. Verhamme¹, A. Yi², A. Segers³, J. Salter², D. Bloomfield², H. Buller⁴, G. Raskob⁵, J. Weitz⁶
Abstract Number: LB 01.3

A Six-week versus Three-month Duration of Anticoagulation for Acute Provoked Venous Thromboembolism in Patients < 21 Years Old: Results of the Multinational Kids-DOTT Randomized Controlled Trial

N.A. Goldenberg¹,², S. Schulman³, J.M. Kittelson⁴, T.C. Abshire⁵,⁶, M. Bonaca⁴,⁷, J.F. Casella⁸, R.A. Dale⁷, J.L. Halperin⁹, F. Hamblin², C.M. Kessler¹0,¹¹, M.J. Manco-Johnson⁴, R.F. Sidonio¹²,¹³, A.C. Spyropoulos¹⁴,¹⁵,¹⁶, P.G. Steg¹⁷, A.G.G. Turpie³, W.R. Hiatt⁴,⁷, Kids-DOTT Trial Investigators§ and the ATLAS Group
Abstract Number: LB 01.4

The Management of SubSegmental Pulmonary Embolism without Anticoagulation

G. Le Gal¹, M. Kovacs², F. Couturaud³, A. Hirsch⁴, M. Huisman⁵, E. Klok⁵, N. Kraaijpoel⁶, M. Righini⁷, M. Rodger⁴, P.-M. Roy⁸, O. Sanchez⁹, J. Schmidt¹0, S. Schulman¹¹, S. Shivakumar¹², A. Trinh-Duc¹³, U. Vinsonneau¹⁴, P. Wells¹, C. Wu¹⁵, E. Yeo¹⁶, M. Carrier¹
Abstract Number: LB 02.1

The VWF-A1 domain binding aptamer BT200 prolongs the half-lives of different factor VIII (FVIII) products in patients with severe hemophilia A and increases FVIII levels in non-severe hemophilia A

C. Ay¹, U. Derhaschnig², B. Jilma², C. Schoergenhofer², K. Kovacevic², P. Quehenberger³, P. Jilma³, J.C. Gilbert⁴, S. Zhu⁴, D. Kraemmer¹, A. Iorio⁵, I. Pabinger¹
Abstract Number: LB 02.2

Towards Understanding ChAdOx1 nCov-19 Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT)

A. Greinacher¹, K. Selleng¹, J. Wesche¹, S. Handtke¹, R. Palankar¹, U. Völker², T. Thiele¹, F. Siegerist³, N. Endlich³, C. Rangaswamy⁴, R.K Mailer⁴, H. Englert⁴, M. Frye⁴, T. Warkentin⁵, T. Renne⁴
Abstract Number: LB 02.3

Mechanism of the development of thrombotic thrombocytopenia in Covid-19 infected patients and after vaccination

T.H. Nguyen¹,², L.-Y. Chen¹,³, N. Khan⁴,⁵, A. Lindenbauer⁶, D. Heinrich⁴,²
Abstract Number: LPB0001

Impact of Heparin Induced Thrombocytopenia on the Outcomes of Hospitalizations for Acute Myocardial Infarction: Analysis of National Inpatient Sample

M.U. Almani¹, M.J. Tariq¹, M. Usman¹, M. Qudrat Ullah², M. Yousuf³, N. Fatima⁴, E. Edigin¹, A. Vij¹, J. Gomez Valencia¹
Abstract Number: LPB0002

Safety and Pharmacokinetics of Direct Oral Anticoagulants after Bariatric Surgery: A Systematic Review

R. Leong¹, D.K Chu^2,3, M.A Crowther², S. Mithoowani²
Abstract Number: LPB0003

Persistence Pattern to Oral Anticoagulants among Non-valvular Atrial Fibrillation Patients who Switched from Vitamin K Antagonists to Direct Oral Anticoagulants: A Cohort Study

M.M. Toorop¹, Q. Chen¹, M.J. Kruip^2,3, F.J. van der Meer¹, M. Nierman⁴, L. Faber⁵, L. Goede⁶, S.C. Cannegieter¹, W.M. Lijfering¹
Abstract Number: LPB0004

Safety and Efficacy of Using Direct Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation Patients with Pre-obesity and Obesity

Q. Chen¹, M.M. Toorop¹, S.C. Cannegieter¹, W.M. Lijfering¹
Abstract Number: LPB0005

Tissue-engineered Human Arteries Replicate Primary and Secondary Haemostatic Functions Seen in vivo: A Replacement for Mouse Arterial Thrombosis Models?

J. Ranjbar¹, Y. Yang¹, A. Harper¹
Abstract Number: LPB0006

Recombinant Heparin: An Old Drug for the Modern World

B.E. Thacker¹, K. Thorne¹, C. Cartwright¹, J. Park¹, K. Glass¹, A. Chea¹, J.D. Esko², W. Jeske³, J.M. Walenga³, C.A. Glass¹
Abstract Number: LPB0007

Activated Protein C (APC) Resistance in FV-W1920R (FV-NARA) Was Caused by the Defective Association between FV-W1920R and Protein S (PS) in the APC/PS/FVa Assembly

N. Shimonishi¹, K. Ogiwara¹, J. Yoshida¹, K. Horie¹, K. Nogami¹
Abstract Number: LPB0008

ADP-induced Platelet-associated Tissue Factor Expression: Unique Involvement of the P2Y12 Receptor and Modulation by Clopidogrel Treatment

M. Brambilla¹, P. Canzano¹, G. Rovati², N. Cosentino¹, A. Becchetti¹, J. Campodonico¹, M. Cattaneo³, D. Trabattoni¹, C. Pinna², E. Tremoli¹, M. Camera²
Abstract Number: LPB0009

Systematic Screening for Pulmonary Embolism in Patients with Suspected Covid-19 in the Emergency Department: A Prospective Cohort Study

I. Luu¹, F. Kroon¹, J. Buijs¹, J. Krdzalic¹, M. de Kruif¹, M. Leers¹, G. Mostard¹, R. Martens¹, R. Mostard¹, D. van Twist¹
Abstract Number: LPB0010

Prevalence of Venous Thromboembolism and Pulmonary Embolism among Patients Hospitalized with a COVID-19 Diagnosis in France

A. Gabet¹, C. Grave¹, P. Tuppin², J. Emmerich³, V. Olié¹
Abstract Number: LPB0011

Immature Platelets as a Biomarker for Disease Severity and Mortality in COVID-19 Patients

D. Welder¹, H. Jeon-Slaughter¹, B. Ashraf¹, S.-H. Choi¹, W. Chen¹, I. Ibrahim¹, T. Bat¹
Abstract Number: LPB0012

Effects of Liraglutide vs. Lifestyle Changes on sST2 and Galectin-3 in Obese Subjects with Prediabetes or Type 2 Diabetes after Comparable Weight Loss

R. Tripaldi¹, P. Simeone¹, R. Liani¹, S. Ciotti¹, A.E. Michelsen², B. Halvorsen², T. Ueland², P. Aukrust², A. Consoli¹, F. Santilli¹
Abstract Number: LPB0013

Evaluation of Heparin-induced Thrombocytopenia Before and during the COVID-19 Pandemic at a US National Reference Laboratory

E. Wong¹, L. Worfolk¹, L. Noh¹, W. Wu¹, M. Sahud², F. Racke², J. Dlott¹